Q32 Bio Inc. (QTTB) – What Are Analysts Saying About This Stock?

Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $32.17.

QTTB has been the subject of a number of recent research reports. Mizuho upgraded Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Leerink Partners assumed coverage on shares of Q32 Bio in a report on Monday, October 12th. They issued an “outperform” rating and a $40.00 target price for the company. Jefferies Financial Group assumed coverage on Q32 Bio in a research report on Monday, September 28th. They set a “buy” rating and a $29.00 price objective on the stock. HC Wainwright increased their price objective on Q32 Bio from $13.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, Oppenheimer restated an “outperform” rating on shares of Q32 Bio in a research note on Thursday, October 1st.

Read Our Latest Report on Q32 Bio

Insider Activity

In other Q32 Bio news, CFO Lee Kalowski sold 3,972 shares of Q32 Bio stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the completion of the sale, the chief financial officer directly owned 138,471 shares in the company, valued at approximately $2,293,079.76. The trade was a 2.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of Q32 Bio stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the transaction, the insider owned 127,771 shares of the company’s stock, valued at $2,115,887.76. The trade was a 2.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 22,054 shares of company stock valued at $320,397. Company insiders own 34.46% of the company’s stock.

Institutional Trading of Q32 Bio

A number of hedge funds have recently added to or reduced their stakes in QTTB. Atlas Venture Life Science Advisors LLC increased its stake in shares of Q32 Bio by 29.9% in the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock valued at $34,616,000 after purchasing an additional 625,000 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Q32 Bio in the third quarter valued at approximately $4,532,000. Marshall Wace LLP increased its position in shares of Q32 Bio by 450.3% in the third quarter. Marshall Wace LLP now owns 368,935 shares of the company’s stock valued at $3,051,000 after buying an additional 301,890 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Q32 Bio during the 3rd quarter worth approximately $2,387,000. Finally, BlackRock Inc. acquired a new position in shares of Q32 Bio during the 2nd quarter worth approximately $1,510,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Price Performance

Shares of Q32 Bio stock opened at $8.53 on Friday. Q32 Bio has a 1 year low of $1.90 and a 1 year high of $23.57. The firm’s 50-day moving average is $9.03 and its 200 day moving average is $9.55. The stock has a market cap of $255.25 million, a price-to-earnings ratio of 2.55 and a beta of 0.45.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. On average, equities analysts expect that Q32 Bio will post -1.42 EPS for the current fiscal year.

About Q32 Bio

(Get Free Report)

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

See Also

Analyst Recommendations for Q32 Bio (NASDAQ:QTTB)

Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.